Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study (Q33347478)

26 July 2017

title

Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

Donald G Gallup

1 reference

26 July 2017

John A Blessing

1 reference

26 July 2017

Willie Andersen

1 reference

26 July 2017

Mark A Morgan

1 reference

26 July 2017

Gynecologic Oncology Group Study

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

26 July 2017

1 reference

26 July 2017

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

48-51

1 reference

Leiomyosarcoma of the uterus

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900136-1

7 January 2021

Leiomyosarcoma of the uterus: clinicopathologic study of 21 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900136-1

7 January 2021

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900136-1

7 January 2021

Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900136-1

7 January 2021

Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900136-1

7 January 2021

Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900136-1

7 January 2021

Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900136-1

7 January 2021

Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900136-1

7 January 2021

Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900136-1

7 January 2021

Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900136-1

7 January 2021

Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900136-1

7 January 2021

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900136-1

7 January 2021

10.1016/S0090-8258(02)00136-1

Identifiers

DOI

1 reference

26 July 2017

1 reference